CAR-T cell therapyFDA-approvedInvestigational
Tisagenlecleucel
How it works
Genetically modifies a patient's T cells to recognize and attack cancer cells, providing a personalized treatment for certain types of leukemia.
Cancer types
Leukemia— Relapsed or refractory B-cell ALL
Efficacy
In clinical trials, around 80% of patients achieved an objective response, with a median overall survival of approximately 2 years.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Study of Tisagenlecleucel in Patients with Leukemia or Lymphoma | Leukemia | phase-3 | — | Source → |
| Evaluating Tisagenlecleucel in Patients with High-Risk B-Cell Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| CAR T-cell therapy outcomes in young leukemia patients | Leukemia | observational | By day 28 postinfusion, 89% of patients achieved complete remission. | Source → |
| New Treatment Option for Relapsed Leukemia Patients | Leukemia | observational | All four patients achieved complete remission after the first InO cycle. | Source → |
| CAR-T Cell Therapy Improves Treatment for Relapsed ALL in Children and Young Adults | Leukemia | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.